文献速递生殖医学妇科

低剂量来曲唑对等待体外受精的症状性子宫腺肌病女性的有效选择:一项初步随机对照试验

Low-dose letrozole - an effective option for women with symptomatic adenomyosis awaiting IVF: a pilot randomized controlled trial.
PubMed 文献 · Reprod Biomed Online · 2023-03-18

这项纵向随机前瞻性初步研究比较低剂量来曲唑与GnRH激动剂治疗3个月对等待IVF的症状性子宫腺肌病女性的效果。两组痛经和月经过多均显著改善,来曲唑组月经规律且无副作用,成本效果更优。低剂量来曲唑是GnRH激动剂的低成本替代方案,效果相当。

要点

  • 来曲唑2.5mg每周三次与戈舍瑞林3.6mg/月治疗3个月均显著降低VAS和PBAC评分。
  • 来曲唑组月经规律,GnRH激动剂组多数闭经,仅4例轻度出血。
  • 来曲唑组无副作用且成本效果优于GnRH激动剂。

核心结论

  • 低剂量来曲唑是GnRH激动剂的低成本替代方案,在改善等待IVF的子宫腺肌病女性症状和超声特征方面效果相当。

研究设计与样本

  • 纵向随机前瞻性初步研究,纳入等待IVF的症状性子宫腺肌病女性,治疗3个月,戈舍瑞林3.6mg/月组n=77,来曲唑2.5mg每周三次组n=79。

主要发现

  • 来曲唑组VAS和PBAC评分在3个月内显著下降(分别为P=0.0001和P=0.0001),GnRH激动剂组同样显著下降(分别为P=0.0001和P=0.0001)。
  • 来曲唑组月经周期规律,GnRH激动剂组多数闭经,仅4例报告轻度出血。
  • 两组血红蛋白浓度均改善(来曲唑P=0.0001,GnRH激动剂P=0.0001)。
  • 超声特征定量评估显示两组均显著改善:肌层弥漫性子宫腺肌病来曲唑P=0.015、GnRH激动剂P=0.039;结合带弥漫性子宫腺肌病来曲唑P=0.025、GnRH激动剂P=0.001。
  • 子宫腺肌瘤两组均反应良好(来曲唑P=0.049,GnRH激动剂P=0.024),而累及外层肌层的局灶性子宫腺肌病来曲唑组反应相对更好(来曲唑P<0.001,GnRH激动剂P=0.26)。

临床怎么用

  • 来曲唑组未观察到明显副作用,且成本效果优于GnRH激动剂治疗。
  • 作者认为低剂量来曲唑治疗是等待IVF的子宫腺肌病女性改善症状和超声特征的低成本替代选择,效果与GnRH激动剂相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Can low-dose letrozole reduce dysmenorrhoea, menorrhagia and sonographic features in symptomatic women with adenomyosis awaiting IVF? DESIGN: This was a longitudinal randomized prospective pilot study to explore the effectiveness of low-dose letrozole and compare it with a gonadotropin releasing hormone (GnRH) agonist in reducing dysmenorrhoea, menorrhagia and sonographic features in symptomatic women with adenomyosis awaiting IVF. The women were treated for 3 months, either with the GnRH agonist goserelin 3.6 mg/month (n = 77) or the aromatase inhibitor letrozole 2.5 mg three times weekly (n = 79). Dysmenorrhoea and menorrhagia were evaluated at randomization and followed up monthly using a visual analogue score (VAS) and pictorial blood loss assessment chart (PBAC), respectively. A quantitative scoring method was used to assess the improvement of sonographic features after 3 months of treatment. RESULTS: Both groups reported a marked improvement in symptoms after 3 months of treatment. In both the letrozole and GnRH agonist groups, VAS and PBAC scores decreased significantly over the 3 months (letrozole: P = 0.0001 and P = 0.0001 for VAS and PBAC, respectively; GnRH agonist: P = 0.0001 and P = 0.0001 for VAS and PBAC, respectively). Participants on letrozole had regular menstruation cycles, while most of the women who received the GnRH agonist were amenorrhoeic, with only four women reporting mild bleeding. Haemoglobin concentrations also improved after both treatments (letrozole P = 0.0001, GnRH agonist P = 0.0001). A quantitative assessment of sonographic features showed significant improvements following both treatments (diffuse adenomyosis of the myometrium: letrozole P = 0.015, GnRH agonist P = 0.039; diffuse adenomyosis of the junctional zone: letrozole P = 0.025, GnRH agonist P = 0.001). Women with adenomyoma also responded well to both therapies (letrozole P = 0.049, GnRH agonist P = 0.024), whereas the letrozole group responded comparatively better in focal adenomyosis when the outer myometrium was involved (letrozole P < 0.001, GnRH agonist P = 0.26). No noticeable side effects were observed in women receiving letrozole therapy. Additionally, letrozole therapy was found to be more cost-effective than GnRH agonist treatment. CONCLUSIONS: Low-dose letrozole treatment is a low-cost alternative to a GnRH agonist, with comparable effects in improving the symptoms and sonographic features of adenomyosis in women awaiting IVF.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Sharma S, RoyChoudhury S, Bhattacharya MP, et al. Low-dose letrozole - an effective option for women with symptomatic adenomyosis awaiting IVF: a pilot randomized controlled trial. Reprod Biomed Online. 2023. PMID: 37149412. doi:10.1016/j.rbmo.2023.03.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。